Gossamer Bio announces seralutinib meets primary endpoint in phase 2 TORREY study in pulmonary arterial hypertension, December 6, 2022

On December 6, 2022, Gossamer Bio, Inc. announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.

Read more about the TORREY study on the Gossamer Bio website at this link

Scroll to Top